It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Complete Listing of the Claims

Claims 1-54 (Canceled)

55. (New) A method of treating a melanoma tumour in a human, comprising administering to cells of said tumour an antisense nucleic acid molecule comprising a sequence that binds to a polynucleotide comprising SEQ ID NO:1 or a corresponding RNA sequence, wherein said nucleic acid molecule has the function of preventing or decreasing expression of human osteonectin.

56. (New) The method of claim 55, wherein said antisense nucleic acid molecule is administered via direct injection to the tumour.

57. (New) The method of claim 55, wherein said antisense nucleic acid molecule is administered *in vitro* to tumour cells taken from said human, and further comprising reintroducing into said human said tumour cells to which said antisense nucleic acid molecule has been administered.

58. (New) The method of claim 55, wherein said antisense nucleic acid molecule is an RNA molecule.

59. (New) The method of claim 55, wherein said antisense nucleic acid molecule is a DNA molecule.

60. (New) A method of treating a melanoma tumour in a human, comprising:

administering *in vitro* to tumour cells taken from said human a nucleic acid molecule comprising a sequence selected from the group consisting of nucleotides 15-1698 of SEQ ID NO:1, the reverse complement thereof, an RNA sequence corresponding to nucleotides 15-1698 of SEQ ID NO:1, and an RNA sequence corresponding to the reverse complement thereof; and

reintroducing into said human said tumour cells to which said nucleic acid molecule has been administered.